Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Metformin

Glucophage · Metformin HCl

Animal replicated

FDA-approvedBiguanide AMPK Activator Small Molecule

RouteOralFDA-approved

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: Biguanide — AMPK Activator — FDA Approved — The World's Most Prescribed Diabetes Drug as a Longevity Candidate — Biguanide, AMPK Activator, Small Molecule.
Why people use it: Used primarily for longevity and anti-aging and weight loss.

If you only read one thing

Metformin has the most compelling epidemiological longevity signal of any compound in this reference — diabetics on metformin outliving healthy non-diabetics in the Bannister study; consistent associations with reduced cancer, cardiovascular events, and dementia in large epidemiological databases; a 2024 Cell paper showing 6.1-year brain aging regression in male primates. The mechanism is coherent: AMPK activation that partially mimics caloric restriction. The TAME trial is the most ambitious longevity pharmacology trial in history. And yet — multiple RCTs confirm that metformin blunts the mitochondrial and anabolic benefits of resistance exercise, creating a genuine trade-off for active individuals. The B12 depletion risk is real, cumulative, and still underappreciated in the community. And the TAME trial results are expected in the late 2020s — the most important pending longevity evidence in human pharmacology. Metformin may be the best longevity investment for sedentary, metabolically compromised, or older adults. It may actively undermine longevity strategy for young, lean, highly active individuals who are already exercising intensively. This dose-population-activity level nuance is the chapter.

Check interactions →

Published literature

10human RCTs5human studies4animal3in vitro

Counts represent major controlled metformin evidence for diabetes/metabolic outcomes plus exercise-interference and prevention studies; TAME and true longevity outcomes are pending and not counted as completed RCT evidence.

Evidence reality check

Human evidence

15 human studies

10 randomized; 5 observational.

Preclinical base

7 lab signals

4 animal; 3 in-vitro/mechanistic.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Longevity & Anti-aging Weight Loss & Metabolic Mitochondrial & Energy Gut & Digestive

Properties

✓ FDA-approved✓ Human RCTNot injectable

Evidence

CAnimal replicated

The TAME Trial

TAME (Targeting Aging with Metformin; NCT03127514; Principal Investigator: Nir Barzilai, Albert Einstein College of Medicine; NIH-funded ~$65M): the first clinical trial to receive FDA agreement to use 'aging' itself as a primary indication endpoint. Design: ~3,000 non-diabetic adults aged 65-79 with or at risk for age-related diseases; metformin 1,500 mg/day vs placebo; follow-up ~6 years; primary composite endpoint: new occurrence of cancer, cardiovascular disease, dementia, disability, or death. TAME is the most important longevity pharmacology trial in history — not just for metformin but for establishing the regulatory framework for anti-aging drug development. Results expected late 2020s.

The Bannister Finding

Bannister CA, et al. (2014, Diabetes, Obesity and Metabolism): UK Clinical Practice Research Datalink; n=78,241 T2D patients on metformin matched to n=78,341 non-diabetic controls. Result: T2D patients on metformin had LOWER all-cause mortality than non-diabetic controls (not just better than untreated T2D — better than healthy non-diabetics). This striking finding launched the modern longevity metformin movement and motivated the TAME trial. The magnitude: metformin users survived longer than comparable healthy people not on the drug. If a drug makes a disease population outlive a healthy control population, it suggests genuine longevity effects beyond disease management.

The Exercise Controversy

Multiple RCTs (2019-2026) have confirmed that metformin partially blunts the mitochondrial adaptations of exercise in older adults — specifically: reduced mitochondrial biogenesis after resistance training; attenuated muscle hypertrophy; reduced satellite cell activity. Mechanism: AMPK activation by metformin suppresses mTORC1, which is required for exercise-induced protein synthesis and mitochondrial biogenesis. For active individuals pursuing longevity primarily through exercise, this creates a genuine trade-off. The TAME trial does not enroll individuals with intensive exercise regimens. The implication: metformin's longevity benefit profile may be most favorable for sedentary or moderately active individuals, and less favorable for those whose primary longevity strategy is high-intensity resistance or endurance training.

B12 Depletion — The Most Important Long-Term Safety Issue

Long-term metformin use depletes vitamin B12 through a well-characterized mechanism: metformin inhibits ileal calcium-dependent vitamin B12-intrinsic factor absorption. Cumulative risk: clinically significant B12 deficiency occurs in approximately 5-30% of long-term metformin users depending on dose and duration. B12 deficiency consequences: peripheral neuropathy (which can masquerade as diabetic neuropathy); subacute combined degeneration of the spinal cord; megaloblastic anemia; cognitive decline. Management: B12 supplementation (1,000 mcg/day methylcobalamin or cyanocobalamin) and B12 monitoring (serum B12 annually during long-term use) are essential for any community metformin user.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

MOTS-c

Same class · AMPK Activator

Mitochondrial-derived peptide studied for AMPK signaling, metabolic stress resilience, and exercise-mimetic pathways.

5-Amino-1MQ

Same class · Small Molecule

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

ATX-304